Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency

NEW YORK& MIAMI--(BUSINESS WIRE) January 21, 2022 -- Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Biologics...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news